524004-38-4

Upstream product

• 1375180-02-1 benzyl 3-(3,4-bis(benzyloxy)phenyl)propanoate 
• 1078-61-1 dihydrocaffeic acid 
• 100-39-0 benzyl bromide 
• 93559-04-7 3-(3,4-bis-benzyloxyphenyl)-propionic acid 
• 1126-20-1 2-allyloxyphenol 
• 1126-61-0 4-allylpyrocatechol 
• 857579-67-0 3-[3,4-bis(benzyloxy)phenyl]prop-1-ene 
• 120-80-9 benzene-1,2-diol 

Downstream Products

• 1370339-85-7 2-[3-(3,4-bis-benzyloxy-phenyl)propyl]isoindole-1,3-dione 
• 1370339-76-6 2-n-butyl-5-chloro-3-[2'-(2-trityl-2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid 3-(3,4-bis-benzyloxyphenyl)propyl ester 
• 1370339-77-7 2-n-butyl-5-chloro-1-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1H-imidazole-4-carboxylic acid 3-(3,4-bis-benzyloxy-phenyl)propyl ester 
• 1370339-78-8 2-n-butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid 3-(3,4-dihydroxyphenyl)propyl ester 
• 1370339-79-9 2-n-butyl-5-chloro-1-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1H-imidazole-4-carboxylic acid 3-(3,4-dihydroxyphenyl)propyl ester 
• 1370339-86-8 2-n-butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid[3-(3,4-bis-benzyloxyphenyl)propyl]amide 
• 1370339-87-9 2-n-butyl-5-chloro-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid[3-(3,4-dihydroxyphenyl)propyl]amide 
• 99281-96-6 3-<3,4-bis(benzyloxy)phenyl>-1-aminopropane 
• 1370339-75-5 2-n-butyl-5-chloro-3H-imidazole-4-carboxylic acid 3-(3,4-bisbenzyloxyphenyl)propyl ester 
• 1440431-81-1 (2'S,4'R,6'S)-2'-(3''',4'''-dihydroxyphenethyl)-6'-(4''''-hydroxy-3''''-methoxyphenyl)tetrahydropyran-4'-yl-3-methoxyphenyl carbamate 
• 1440432-12-1 (2S,4R,6S)-2-(3'',4''-dihydroxyphenethyl)-6-(3'''-bromo-4'''-hydroxy-5'''-methoxyphenyl)tetrahydropyran-4-yl-3''''-(4'''''-methoxyphenyl)propyl carbonate 
• 95301-39-6 3-(3',4'-dibenzyloxyphenyl)propanal 
• 1440432-71-2 (S)-1-(3′,4′-dibenzyloxyphenyl)hex-5-ene-3-ol 

Relevant academic research and scientific papers

NANO-ADHESIVE AND SURFACE PRIMER COMPOUND AND USE THEREOF

A compound for self-assembly onto a mineral and/or metal oxides substrate, the compound comprising a catechol group attached to an end group through a spacer group. The compound include a structure of Formula (I):

Hybridization of β-Adrenergic Agonists and Antagonists Confers G Protein Bias

Starting from the β-adrenoceptor agonist isoprenaline and beta-blocker carvedilol, we designed and synthesized three different chemotypes of agonist/antagonist hybrids. Investigations of ligand-mediated receptor activation using bioluminescence resonance energy transfer biosensors revealed a predominant effect of the aromatic head group on the intrinsic activity of our ligands, as ligands with a carvedilol head group were devoid of agonistic activity. Ligands composed of a catechol head group and an antagonist-like oxypropylene spacer possess significant intrinsic activity for the activation of Gαs, while they only show weak or even no β-arrestin-2 recruitment at both β1- and β2-AR. Molecular dynamics simulations suggest that the difference in G protein efficacy and β-arrestin recruitment of the hybrid (S)-22, the full agonist epinephrine, and the β2-selective, G protein-biased partial agonist salmeterol depends on specific hydrogen bonding between Ser5.46 and Asn6.55, and the aromatic head group of the ligands.

PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE

In one embodiment, the present application discloses a photo-cleavable surface binding compound of the Formula I and Formula II: wherein the variables EG, EG1, SP1, SP2, SP3, Ar and BG are as defined herein. In another embodiment, the application discloses a method for forming a coating on a surface of a substrate using the surface binding compound.

New losartan-hydrocaffeic acid hybrids as antihypertensive-antioxidant dual drugs: Ester, amide and amine linkers

We report new examples of a series of losartan-hydrocaffeic hybrids that bear novel ester, amide and amine linkers. These compounds were made by linking hydrocaffeic acid to the side chain of losartan at the C-5 position of the imidazole ring through different strategies. Experiments performed in cultured cells demonstrate that these new hybrids retain the ability to block the angiotensin II effect and have increased antioxidant ability. Most of them reduced arterial pressure in rats better or as much as losartan.